Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Life Threatening Diseases
Interventions: DRUG: Imatinib mesylate
Sponsor: Novartis Pharmaceuticals